1332-40-7

Applied Filters:

Keyword:'1332-40-7'

Showing 1-10 of 869 results for "1332-40-7" within Site Content

Solvent Analysis for 40 Per and Polyfluoroalkyl Substances

Trace-level PFAS analysis of solvents using SPE and LC-MS/MS to verify purity, method performance, and suitability for regulatory testing workflows.

Determination of 7 Nitrosamines in Drinking Water

Nitrosamines analysis by solid phase extraction (SPE) and subsequent gas chromatography-tandem mass spectrometry (GC-MS/MS) according to GB 5750.10-2023.

Color Determination of Sugar based on ICUMSA Color GS1-7

Learn about the ICUMSA® method GS1-7 to measure the color of sample solutions of raw sugar, brown sugar, or sugar syrups.

Recovery of PFAS via OTM-45 Using PFAS Resin

Ready-to-use Supelpak™-2 4PFAS resin shows no background contamination and reliable recovery of 40 PFAS for LC-MS/MS emission and air monitoring compliance.

US EPA Method 325B Compliance

The new US federal regulation 40 CFR Parts 60 and 63 – Petroleum Refinery Sector Risk and Technology Review and New Source Performance Standards, is an update to the previous version.

Recent Developments in Silicon Anode Materials for High Performance Lithium-Ion Batteries

Recent demand for electric and hybrid vehicles, coupled with a reduction in prices, has caused lithium-ion batteries (LIBs) to become an increasingly popular form of rechargeable battery technology.

Estimation of Proline in Fruit and Vegetable Juices

Spectrophotometric determination of proline by the Ninhydrin method, per EN 1141 and German Food and Feed Code §64 LFBG 31.00-7.

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

RNA Therapeutics & Delivery USA

Visit us at booth #7 to learn about our solutions to help you overcome your mRNA manufacturing and LNP formulation challenges.

cOmplete™, Mini, EDTA-free Protocol

Dissolve one tablet in 10 ml aqueous buffer or water. If high proteolytic activity is present, dissolve one tablet in 7 ml buffer.

Page 1 of 87